Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ADH5 | P11766 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3683659 | 0.86 | CCNC (0.44) | CCNCCDK8TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL3678455 | 0.77 | CCNC (0.52) | CCNCCDK8TBXAS1CYP1A2CYP11B1 | |
| SCHEMBL3678452 | 0.77 | CCNC (0.52) | CCNCCDK8TBXAS1CYP1A2CYP11B1 | |
| SCHEMBL3683679 | 0.75 | FFAR4 (0.60) | CCNCCDK8FFAR4CYP1A2FFAR1 | |
| SCHEMBL3680372 | 0.72 | FFAR4 (0.56) | CCNCCDK8FFAR4CYP1A2FFAR1 | |
| SCHEMBL8451511 | 0.72 | FFAR1 (0.71) | CCNCCDK8FFAR4CYP1A2FFAR1 | |
| SCHEMBL5748903 | 0.72 | CCNC (0.51) | CCNCCDK8FFAR4CYP1A2FFAR1 | |
| SCHEMBL1217683 | 0.71 | CYP1A2 (0.80) | FFAR4CYP1A2FFAR1CYP2C19 | |
| SCHEMBL30403190 | 0.71 | CYP1A2 (0.80) | FFAR4CYP1A2FFAR1CYP2C19 | |
| SCHEMBL3882947 | 0.71 | FFAR4 (0.80) | CCNCCDK8FFAR4CYP1A2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7470807-B2 | Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-12-30 | — | — | US | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CCNC 3082/4885CDK8 4033/4885FFAR4 35/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CCNC 3082/4885CDK8 4033/4885FFAR4 35/4885 |
| US-20090062530-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CCNC 3082/4885CDK8 4033/4885FFAR4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.